Terms: = Thyroid cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
15 results:
1. Drug-induced inhibition of HMGA and ezh2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract] [Full Text] [Related]
2. Modulation of ezh2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic thyroid cancer.
de Mello DC; Saito KC; Cristovão MM; Kimura ET; Fuziwara CS
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175580
[TBL] [Abstract] [Full Text] [Related]
3. Validation of ezh2 Inhibitor Efficiency in Anaplastic thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population.
Tao X; Xu T; Lin X; Xu S; Fan Y; Guo B; Deng X; Jiao Q; Chen L; Wei Z; Chen C; Yang W; Zhang Z; Yu X; Yue H
J Clin Endocrinol Metab; 2023 Jun; 108(7):1768-1775. PubMed ID: 36611251
[TBL] [Abstract] [Full Text] [Related]
5. Single-Cell Analyses Reveal Mechanisms of cancer Stem Cell Maintenance and Epithelial-Mesenchymal Transition in Recurrent Bladder cancer.
Wang H; Mei Y; Luo C; Huang Q; Wang Z; Lu GM; Qin L; Sun Z; Huang CW; Yang ZW; Chen J; Yin W; Qian CN; Zeng J; Chen L; Leng Q; Guo Y; Jia G
Clin Cancer Res; 2021 Nov; 27(22):6265-6278. PubMed ID: 34526362
[TBL] [Abstract] [Full Text] [Related]
6. Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.
Osako T; Lee H; Turashvili G; Chiu D; McKinney S; Joosten SEP; Wilkinson D; Nielsen TO; Zwart W; Emerman JT; Eaves CJ; Caldas C; Aparicio S
Nat Cancer; 2020 May; 1(5):518-532. PubMed ID: 35121983
[TBL] [Abstract] [Full Text] [Related]
7. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
Fu H; Cheng L; Sa R; Jin Y; Chen L
J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
[TBL] [Abstract] [Full Text] [Related]
8. UNC5B-AS1 promoted ovarian cancer progression by regulating the H3K27me on NDRG2 via ezh2.
Wang H; Su H; Tan Y
Cell Biol Int; 2020 Apr; 44(4):1028-1036. PubMed ID: 31903696
[TBL] [Abstract] [Full Text] [Related]
9. Salutary Response to Targeted Therapy in Anaplastic thyroid cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
10. ezh2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract] [Full Text] [Related]
11. Targeting ezh2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.
Wang Z; Dai J; Yan J; Zhang Y; Yin Z
J Cell Mol Med; 2019 Jul; 23(7):4770-4778. PubMed ID: 31087496
[TBL] [Abstract] [Full Text] [Related]
12. Decreased expression of ezh2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells.
Yu P; Guo Y; Yusufu M; Liu Z; Wang S; Yin X; Peng G; Wang L; Zhao X; Guo H; Huang T; Liu C
Cell Biol Int; 2016 Oct; 40(10):1062-70. PubMed ID: 27436059
[TBL] [Abstract] [Full Text] [Related]
13. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
[TBL] [Abstract] [Full Text] [Related]
14. Prevalence of cancer in Italian obese patients referred for bariatric surgery.
Boru C; Silecchia G; Pecchia A; Iacobellis G; Greco F; Rizzello M; Basso N
Obes Surg; 2005 Sep; 15(8):1171-6. PubMed ID: 16197792
[TBL] [Abstract] [Full Text] [Related]
15. thyroid carcinoma after radioactive iodine therapy for Graves' disease.
Ozaki O; Ito K; Mimura T; Sugino K; Kitamura Y; Iwabuchi H; Kawano M
World J Surg; 1994; 18(4):518-21. PubMed ID: 7725738
[TBL] [Abstract] [Full Text] [Related]
